{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:54:32Z","timestamp":1760241272125,"version":"build-2065373602"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Probes"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.mcp.2022.101817","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T11:23:02Z","timestamp":1650021782000},"page":"101817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The tricks for fighting against cancer using CAR NK cells: A review"],"prefix":"10.1016","volume":"63","author":[{"given":"Fatemeh","family":"Vahidian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila Mohamed","family":"Khosroshahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moloud","family":"Akbarzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Jahanban-Esfahlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Baghbanzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Ali-Hassanzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Safarzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib1","first-page":"477","article-title":"Selection and expansion of natural killer cells for NK cell-based immunotherapy, Cancer Immunology","volume":"65","author":"Becker","year":"2016","journal-title":"Immunotherapy"},{"issue":"12","key":"10.1016\/j.mcp.2022.101817_bib2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nri956","article-title":"Natural killer cells and dendritic cells: rendezvous in abused tissues","volume":"2","author":"Moretta","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.mcp.2022.101817_bib3","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1084\/jem.20011149","article-title":"Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells","volume":"195","author":"Ferlazzo","year":"2002","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.imbio.2015.07.012","article-title":"Tricking the balance: NK cells in anti-cancer immunity","volume":"222","author":"Pahl","year":"2017","journal-title":"Immunobiology"},{"issue":"5562","key":"10.1016\/j.mcp.2022.101817_bib5","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.mcp.2022.101817_bib6","first-page":"821","article-title":"Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy, Cancer Immunology","volume":"63","author":"Brehm","year":"2014","journal-title":"Immunotherapy"},{"issue":"11","key":"10.1016\/j.mcp.2022.101817_bib7","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jcyt.2015.07.011","article-title":"A phase I\/II trial of interleukin-15\u2013stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors","volume":"17","author":"P\u00e9rez-Mart\u00ednez","year":"2015","journal-title":"Cytotherapy"},{"issue":"26","key":"10.1016\/j.mcp.2022.101817_bib8","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib9","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.mcp.2022.101817_bib10","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.3389\/fonc.2021.673276","article-title":"A new paradigm in tumor immunotherapy","volume":"11","author":"Marofi","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-021-02462-y","article-title":"CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"issue":"11","key":"10.1016\/j.mcp.2022.101817_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural killer cells and other innate lymphoid cells in cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.mcp.2022.101817_bib13","first-page":"77","article-title":"Natural killer cells in cancer immunotherapy","volume":"3","author":"Miller","year":"2019","journal-title":"Annu. Rev. Cell Biol."},{"key":"10.1016\/j.mcp.2022.101817_bib14","unstructured":"A. Das, A. Dutta, S. Paul, A. Dutta, A. Bhattacharya, S. Banerjee, D.D. Chowdhury, U. Basak, P. Khan, D. Mazumdar, Cancer Stem Cells, Their Origin and Niche: A Search for the Therapeutic Target."},{"issue":"5","key":"10.1016\/j.mcp.2022.101817_bib15","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib16","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.18632\/oncotarget.12739","article-title":"The concept of immune surveillance against tumors: the first theories","volume":"8","author":"Ribatti","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.mcp.2022.101817_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu. Rev. Immunol."},{"issue":"6832","key":"10.1016\/j.mcp.2022.101817_bib18","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFN\u03b3 and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"issue":"7171","key":"10.1016\/j.mcp.2022.101817_bib19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02587.x","article-title":"Cancer immunoediting from immune surveillance to immune escape","volume":"121","author":"Kim","year":"2007","journal-title":"Immunology"},{"year":"2007","series-title":"Tumor Infiltrating Lymphocytes: Indicators of Tumor-Related Immune Responses","author":"Odunsi","key":"10.1016\/j.mcp.2022.101817_bib21"},{"issue":"7","key":"10.1016\/j.mcp.2022.101817_bib22","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1016700","article-title":"Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells","volume":"4","author":"Wu","year":"2015","journal-title":"OncoImmunology"},{"issue":"10","key":"10.1016\/j.mcp.2022.101817_bib23","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/carcin\/bgv123","article-title":"Immunosuppression associated with chronic inflammation in the tumor microenvironment","volume":"36","author":"Wang","year":"2015","journal-title":"Carcinogenesis"},{"issue":"16","key":"10.1016\/j.mcp.2022.101817_bib24","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/jnci\/djt184","article-title":"MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells","volume":"105","author":"Leone","year":"2013","journal-title":"J. Nat. Cancer Insitute."},{"issue":"suppl_12","key":"10.1016\/j.mcp.2022.101817_bib25","article-title":"Mechanisms regulating T-cell infiltration and activity in solid tumors","volume":"28","author":"Lanitis","year":"2017","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.mcp.2022.101817_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.mcp.2022.101817_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002711","article-title":"Deep learning for lung cancer prognostication: a retrospective multi-cohort radiomics study","volume":"15","author":"Hosny","year":"2018","journal-title":"PLoS Med."},{"key":"10.1016\/j.mcp.2022.101817_bib28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fimmu.2016.00179","article-title":"A new biological feature of natural killer cells: the recognition of solid tumor-derived cancer stem cells","volume":"7","author":"Tallerico","year":"2016","journal-title":"Front. Immunol."},{"issue":"6013","key":"10.1016\/j.mcp.2022.101817_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/eji.1830050208","article-title":"\u201eNatural\u201d killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/eji.1830050209","article-title":"\u201eNatural\u201d killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell","volume":"5","author":"Kiessling","year":"1975","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ijc.2910160204","article-title":"Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity","volume":"16","author":"Herberman","year":"1975","journal-title":"Int. J. Cancer"},{"issue":"24","key":"10.1016\/j.mcp.2022.101817_bib33","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1182\/blood-2008-06-165225","article-title":"Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity","volume":"113","author":"Woll","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.mcp.2022.101817_bib34","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fimmu.2014.00095","article-title":"Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies","volume":"5","author":"Chouaib","year":"2014","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.mcp.2022.101817_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020740","article-title":"Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process","volume":"6","author":"Spanholtz","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.mcp.2022.101817_bib36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/cmi.2013.10","article-title":"NK cell-based immunotherapy for malignant diseases","volume":"10","author":"Cheng","year":"2013","journal-title":"Cell. Mol. Immunol."},{"issue":"10","key":"10.1016\/j.mcp.2022.101817_bib37","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1182\/blood.V97.10.3146","article-title":"Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset","volume":"97","author":"Cooper","year":"2001","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mcp.2022.101817_bib38","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.166.11.6477","article-title":"Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire","volume":"166","author":"Campbell","year":"2001","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib39","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1073\/pnas.1012356108","article-title":"Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN-\u03b3 on activation","volume":"108","author":"De Maria","year":"2011","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"3","key":"10.1016\/j.mcp.2022.101817_bib40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.mcp.2022.101817_bib41","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol."},{"issue":"7","key":"10.1016\/j.mcp.2022.101817_bib42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/intimm\/dxr035","article-title":"The \u2018T-cell-ness' of NK cells: unexpected similarities between NK cells and T cells","volume":"23","author":"Narni-Mancinelli","year":"2011","journal-title":"Int. Immunol."},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/cmi.2016.26","article-title":"NK cell education via nonclassical MHC and non-MHC ligands","volume":"14","author":"He","year":"2017","journal-title":"Cell. Mol. Immunol."},{"issue":"6","key":"10.1016\/j.mcp.2022.101817_bib44","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/0008-5472.CAN-12-3558","article-title":"A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.mcp.2022.101817_bib45","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3389\/fimmu.2017.00745","article-title":"Natural Killer cell-Based cancer immunotherapies: from immune evasion to Promising targeted cellular therapies","volume":"8","author":"Hofer","year":"2017","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.mcp.2022.101817_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2005.10.001","article-title":"Human natural killer cell development and biology","volume":"20","author":"Farag","year":"2006","journal-title":"Blood Rev."},{"issue":"18","key":"10.1016\/j.mcp.2022.101817_bib47","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1182\/blood-2010-10-311456","article-title":"Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques","volume":"117","author":"Waldmann","year":"2011","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.mcp.2022.101817_bib48","doi-asserted-by":"crossref","first-page":"14725","DOI":"10.1073\/pnas.1110900108","article-title":"Expansion of a unique CD57+ NKG2Chi natural killer cell subset during acute human cytomegalovirus infection","volume":"108","author":"Lopez-Verg\u00e8s","year":"2011","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.mcp.2022.101817_bib49","first-page":"133","article-title":"Effects of Peptide on NK cell-mediated MHC I recognition","volume":"5","author":"Khakoo","year":"2014","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib50","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/JVI.80.1.545-550.2006","article-title":"Expression of m157, a murine cytomegalovirus-encoded putative major histocompatibility class I (MHC-I)-like protein, is independent of viral regulation of host MHC-I","volume":"80","author":"Tripathy","year":"2006","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/cyto.b.21508","article-title":"Markers and function of human NK cells in normal and pathological conditions","volume":"92","author":"Del Zotto","year":"2017","journal-title":"Cytometry B Clin. Cytometry"},{"issue":"9","key":"10.1016\/j.mcp.2022.101817_bib52","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3390\/ijms18091868","article-title":"Natural killer cells: angels and devils for immunotherapy","volume":"18","author":"Mart\u00edn-Antonio","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"5428","key":"10.1016\/j.mcp.2022.101817_bib53","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA","volume":"285","author":"Bauer","year":"1999","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib54","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1073\/pnas.93.4.1453","article-title":"Physical and functional independency of p70 and p58 natural killer (NK) cell receptors for HLA class I: their role in the definition of different groups of alloreactive NK cell clones","volume":"93","author":"Vitale","year":"1996","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1074-7613(01)00095-4","article-title":"ULBPs, novel MHC class I\u2013related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor","volume":"14","author":"Cosman","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.mcp.2022.101817_bib56","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.23.021704.115526","article-title":"NK cell recognition","volume":"23","author":"Lanier","year":"2005","journal-title":"Annu. Rev. Immunol."},{"issue":"17","key":"10.1016\/j.mcp.2022.101817_bib57","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2013-03-489054","article-title":"Identification of a cellular ligand for the natural cytotoxicity receptor NKp44","volume":"122","author":"Baychelier","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1074-7613(00)80529-4","article-title":"A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules","volume":"7","author":"Cosman","year":"1997","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.mcp.2022.101817_bib59","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1084\/jem.20090681","article-title":"The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans","volume":"206","author":"Brandt","year":"2009","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.mcp.2022.101817_bib60","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.immuni.2007.10.010","article-title":"Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells","volume":"27","author":"von Strandmann","year":"2007","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.mcp.2022.101817_bib61","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.4049\/jimmunol.1102267","article-title":"Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44","volume":"187","author":"Rosental","year":"2011","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.mcp.2022.101817_bib62","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1172\/JCI36022","article-title":"NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo","volume":"119","author":"Lakshmikanth","year":"2009","journal-title":"J. Clinic. Invest."},{"key":"10.1016\/j.mcp.2022.101817_bib63","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.mcp.2022.101817_bib64","first-page":"11","article-title":"Signal transduction during activation and inhibition of natural killer cells","author":"Watzl","year":"2010","journal-title":"Curr. Protoc. Im."},{"issue":"5","key":"10.1016\/j.mcp.2022.101817_bib65","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nri1603","article-title":"A new self: MHC-class-I-independent natural-killer-cell self-tolerance","volume":"5","author":"Kumar","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"6624","key":"10.1016\/j.mcp.2022.101817_bib66","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/386510a0","article-title":"Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo","volume":"386","author":"Farrell","year":"1997","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.mcp.2022.101817_bib67","doi-asserted-by":"crossref","first-page":"23823","DOI":"10.1074\/jbc.M110.214254","article-title":"Molecular basis for LLT1 protein recognition by human CD161 protein (NKRP1A\/KLRB1)","volume":"286","author":"Kamishikiryo","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib68","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2007.03.006","article-title":"Dendritic cells prime natural killer cells by trans-presenting interleukin 15","volume":"26","author":"Lucas","year":"2007","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.mcp.2022.101817_bib69","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.immuni.2009.09.017","article-title":"Macrophage-and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets","volume":"31","author":"Mortier","year":"2009","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.mcp.2022.101817_bib70","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1182\/blood-2007-11-122259","article-title":"A role for interleukin-12\/23 in the maturation of human natural killer and CD56+ T cells in vivo","volume":"111","author":"Guia","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mcp.2022.101817_bib71","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.4049\/jimmunol.181.3.1627","article-title":"Cutting edge: priming of NK cells by IL-18","volume":"181","author":"Chaix","year":"2008","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.mcp.2022.101817_bib72","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/nri3839","article-title":"Perforin and granzymes: function, dysfunction and human pathology","volume":"15","author":"Voskoboinik","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.mcp.2022.101817_bib73","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.4049\/jimmunol.172.5.3119","article-title":"Coordinate expression of cytokines and chemokines by NK cells during murine cytomegalovirus infection","volume":"172","author":"Dorner","year":"2004","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.mcp.2022.101817_bib74","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/eji.200324070","article-title":"Regulation of perforin\u2010independent NK cell\u2010mediated cytotoxicity","volume":"33","author":"Wallin","year":"2003","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib75","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1189\/jlb.5VMR0415-141R","article-title":"Natural killer (NK) cells and anti\u2010tumor therapeutic mAb: unexplored interactions","volume":"99","author":"Battella","year":"2016","journal-title":"J. Leukoc. Biol."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib77","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3892\/ol.2014.2099","article-title":"Effects of complement and serum IgG on rituximab-dependent natural killer cell-mediated cytotoxicity against Raji cells","volume":"17","author":"Li","year":"2019","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib78","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.180.2.569","article-title":"Identification of a common T\/natural killer cell progenitor in human fetal thymus","volume":"180","author":"Sanchez","year":"1994","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.mcp.2022.101817_bib79","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1182\/blood.V85.10.2654.bloodjournal85102654","article-title":"Development of human T and natural killer cells","volume":"85","author":"Spits","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.mcp.2022.101817_bib80","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4049\/jimmunol.172.3.1333","article-title":"NK cell compartments and their activation by dendritic cells","volume":"172","author":"Ferlazzo","year":"2004","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib81","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1074-7613(03)00264-4","article-title":"Natural killer cells activated by MHC class Ilow targets prime dendritic cells to induce protective CD8 T cell responses","volume":"19","author":"Mocikat","year":"2003","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.mcp.2022.101817_bib82","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/ni1138","article-title":"Induced recruitment of NK cells to lymph nodes provides IFN-\u03b3 for T H 1 priming","volume":"5","author":"Mart\u00edn-Fontecha","year":"2004","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib83","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood.V97.1.192","article-title":"Perforin and interferon-\u03b3 activities independently control tumor initiation, growth, and metastasis","volume":"97","author":"Street","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.mcp.2022.101817_bib84","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20112738","article-title":"Cancer immunoediting by the innate immune system in the absence of adaptive immunity","volume":"209","author":"O'Sullivan","year":"2012","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.mcp.2022.101817_bib85","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1084\/jem.20010934","article-title":"Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells","volume":"195","author":"Piccioli","year":"2002","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.mcp.2022.101817_bib86","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1371\/journal.ppat.0030123","article-title":"Natural killer cells promote early CD8 T cell responses against cytomegalovirus","volume":"3","author":"Robbins","year":"2007","journal-title":"PLoS Pathog."},{"issue":"26","key":"10.1016\/j.mcp.2022.101817_bib87","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1182\/blood-2009-01-201467","article-title":"NK cell\u2013mediated killing of target cells triggers robust antigen-specific T cell\u2013mediated and humoral responses","volume":"113","author":"Krebs","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.mcp.2022.101817_bib88","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fimmu.2017.01143","article-title":"Natural killer cell memory: progress and implications","volume":"8","author":"Peng","year":"2017","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.mcp.2022.101817_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003548","article-title":"Memory of infections: an emerging role for natural killer cells","volume":"9","author":"R\u00f6lle","year":"2013","journal-title":"PLoS Pathog."},{"year":"2009","series-title":"NK Cells Stroll Down the Memory Lane","author":"Pyzik","key":"10.1016\/j.mcp.2022.101817_bib90"},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib91","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.0105-2896.2010.00906.x","article-title":"Adaptive immune responses mediated by natural killer cells","volume":"235","author":"Paust","year":"2010","journal-title":"Immunol. Rev."},{"issue":"23","key":"10.1016\/j.mcp.2022.101817_bib92","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.mcp.2022.101817_bib93","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat. Immunol."},{"issue":"14","key":"10.1016\/j.mcp.2022.101817_bib94","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.2217\/imt-2019-0040","article-title":"Natural killer cells and cancer therapy, what we know and where we are going","volume":"11","author":"Ghaemdoust","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.mcp.2022.101817_bib95","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0167-5699(90)90097-S","article-title":"In search of the \u2018missing self\u2019: MHC molecules and NK cell recognition","volume":"11","author":"Ljunggren","year":"1990","journal-title":"Immunol. Today"},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib96","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.cdd.4402244","article-title":"Mechanisms of granule-dependent killing","volume":"15","author":"Cullen","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.mcp.2022.101817_bib97","first-page":"1","article-title":"NK cells for cancer immunotherapy","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"21","key":"10.1016\/j.mcp.2022.101817_bib98","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2007.15.7198","article-title":"Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2\/tumor necrosis factor\u2013related apoptosis-inducing ligand (rhApo2L\/TRAIL)","volume":"26","author":"Ashkenazi","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.mcp.2022.101817_bib99","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/odi.12496","article-title":"Helper and cytotoxic T\u2010cell subsets (Th1, Th2, Tc1, and Tc2) in benign and malignant salivary gland tumors","volume":"22","author":"Haghshenas","year":"2016","journal-title":"Oral Dis."},{"issue":"19","key":"10.1016\/j.mcp.2022.101817_bib100","first-page":"5155","article-title":"Inhibition of angiogenesis by interferons: effects on tumor-and lymphocyte-induced vascular responses","volume":"47","author":"Sidky","year":"1987","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.mcp.2022.101817_bib101","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.4049\/jimmunol.1101988","article-title":"Immune surveillance properties of human NK cell-derived exosomes","volume":"189","author":"Lugini","year":"2012","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib102","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/cdd.2013.26","article-title":"Molecular mechanisms of natural killer cell activation in response to cellular stress","volume":"21","author":"Chan","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.mcp.2022.101817_bib103","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3389\/fmolb.2021.669366","article-title":"Potential role of Hsp70 and activated NK cells for prediction of prognosis in glioblastoma patients","volume":"8","author":"Lobinger","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"49","key":"10.1016\/j.mcp.2022.101817_bib104","doi-asserted-by":"crossref","first-page":"20847","DOI":"10.1073\/pnas.0906481106","article-title":"Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity","volume":"106","author":"Balsamo","year":"2009","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib105","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2011.12.020","article-title":"Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and Ido","volume":"318","author":"Li","year":"2012","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib106","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000323936","article-title":"Modulation of natural killer cell anti-tumor reactivity by platelets","volume":"3","author":"Placke","year":"2011","journal-title":"J. Innate. Immun."},{"issue":"8","key":"10.1016\/j.mcp.2022.101817_bib107","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxw025","article-title":"Roles of regulatory T cells in cancer immunity","volume":"28","author":"Takeuchi","year":"2016","journal-title":"Int. Immunol."},{"issue":"11","key":"10.1016\/j.mcp.2022.101817_bib108","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s12272-016-0822-9","article-title":"Signal transducer and activator of transcription proteins: regulators of myeloid-derived suppressor cell-mediated immunosuppression in cancer","volume":"39","author":"Ko","year":"2016","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"11","key":"10.1016\/j.mcp.2022.101817_bib109","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s12272-016-0820-y","article-title":"Diverse macrophages polarization in tumor microenvironment","volume":"39","author":"Rhee","year":"2016","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"8","key":"10.1016\/j.mcp.2022.101817_bib110","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.4049\/jimmunol.0901226","article-title":"Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells","volume":"183","author":"Carlsten","year":"2009","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib111","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","article-title":"Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization","volume":"139","author":"Pesce","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"7","key":"10.1016\/j.mcp.2022.101817_bib112","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1084\/jem.20050167","article-title":"Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules","volume":"201","author":"Johansson","year":"2005","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib113","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1146\/annurev.immunol.21.120601.141110","article-title":"T cell anergy","volume":"21","author":"Schwartz","year":"2003","journal-title":"Annu. Rev. Immunol."},{"issue":"21","key":"10.1016\/j.mcp.2022.101817_bib114","doi-asserted-by":"crossref","first-page":"10365","DOI":"10.1073\/pnas.89.21.10365","article-title":"Adaptive cellular interactions in the immune system: the tunable activation threshold and the significance of subthreshold responses","volume":"89","author":"Grossman","year":"1992","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"6","key":"10.1016\/j.mcp.2022.101817_bib115","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0952-7915(01)00280-1","article-title":"Autoreactivity, dynamic tuning and selectivity","volume":"13","author":"Grossman","year":"2001","journal-title":"Curr. Opin. Immunol."},{"year":"2018","series-title":"FDA Approves Second CAR T-Cell Therapy","author":"Calmes-Miller","key":"10.1016\/j.mcp.2022.101817_bib116"},{"issue":"8","key":"10.1016\/j.mcp.2022.101817_bib117","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.mcp.2022.101817_bib118","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","article-title":"Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity","volume":"8","author":"Zhang","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mcp.2022.101817_bib119","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fphar.2015.00021","article-title":"Advantages and applications of CAR-expressing natural killer cells","volume":"6","author":"Glienke","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mcp.2022.101817_bib120","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.coi.2016.06.004","article-title":"Chimeric antigen receptors: driving immunology towards synthetic biology","volume":"41","author":"Sadelain","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib121","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4049\/jimmunol.151.1.60","article-title":"A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells","volume":"151","author":"Garni-Wagner","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.mcp.2022.101817_bib122","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3389\/fimmu.2017.00654","article-title":"Redirected primary human chimeric antigen receptor natural killer cells as an \u201coff-the-shelf immunotherapy\u201d for improvement in cancer treatment","volume":"8","author":"Oberschmidt","year":"2017","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.mcp.2022.101817_bib123","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/2326-6066.CIR-15-0118","article-title":"Phase I study of random healthy donor\u2013derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors","volume":"4","author":"Yang","year":"2016","journal-title":"Cancer. Immunol. Res."},{"key":"10.1016\/j.mcp.2022.101817_bib124","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fimmu.2017.00329","article-title":"Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications","volume":"8","author":"Sarvaria","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mcp.2022.101817_bib125","doi-asserted-by":"crossref","unstructured":"D.L. Porter, E.O. Hexner, S. Cooley, J.S. Miller, Cellular Adoptive Immunotherapy after Autologous and Allogeneic Hematopoietic Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation, Springer2009, pp. 497-537.","DOI":"10.1007\/978-0-387-78580-6_20"},{"issue":"10","key":"10.1016\/j.mcp.2022.101817_bib126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076781","article-title":"Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mcp.2022.101817_bib127","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.exphem.2016.10.003","article-title":"Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: potential for adoptive cellular immunotherapy","volume":"46","author":"Ayello","year":"2017","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib128","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.mcp.2022.101817_bib129","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fimmu.2015.00195","article-title":"Utilizing chimeric antigen receptors to direct natural killer cell activity","volume":"6","author":"Hermanson","year":"2015","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1074-7613(00)80300-3","article-title":"Recruitment of tyrosine phosphatase HCP by the killer cell inhibitory receptor","volume":"4","author":"Burshtyn","year":"1996","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.mcp.2022.101817_bib131","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/jcmm.12810","article-title":"CD 19\u2010CAR engineered NK\u201092 cells are sufficient to overcome NK cell resistance in B\u2010cell malignancies","volume":"20","author":"Romanski","year":"2016","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib132","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/stem.2230","article-title":"Induced pluripotent stem cell\u2010derived natural killer cells for treatment of ovarian cancer","volume":"34","author":"Hermanson","year":"2016","journal-title":"Stem Cell."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib133","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1250050","article-title":"Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G","volume":"6","author":"Kailayangiri","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.mcp.2022.101817_bib134","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fimmu.2018.00283","article-title":"Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer","volume":"9","author":"Mehta","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3892\/or.2020.7862","article-title":"Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK-92 cells","volume":"33","author":"Liu","year":"2015","journal-title":"Oncol. Rep."},{"issue":"9","key":"10.1016\/j.mcp.2022.101817_bib136","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1341031","article-title":"Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice","volume":"6","author":"Chu","year":"2017","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib137","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.molonc.2013.12.001","article-title":"Transfection of chimeric anti\u2010CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells","volume":"8","author":"Jiang","year":"2014","journal-title":"Mol. Oncol."},{"year":"2017","series-title":"Daratumumab Combined with CD38 (-) Natural Killer Cells Armed with a CS1 Chimeric Antigen Receptor for the Treatment of Relapsed Multiple Myeloma","author":"Wang","key":"10.1016\/j.mcp.2022.101817_bib138"},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib139","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/cgt.2011.66","article-title":"Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor","volume":"19","author":"Tassev","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.mcp.2022.101817_bib140","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.canlet.2019.11.033","article-title":"CAR-NK for tumor immunotherapy: clinical transformation and future prospects","volume":"472","author":"Wang","year":"2020","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib141","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.mcp.2022.101817_bib142","doi-asserted-by":"crossref","first-page":"11483","DOI":"10.1038\/srep11483","article-title":"CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells","volume":"5","author":"Han","year":"2015","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.mcp.2022.101817_bib143","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.4049\/jimmunol.1400330","article-title":"DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy","volume":"194","author":"T\u00f6pfer","year":"2015","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.mcp.2022.101817_bib144","first-page":"djv375","article-title":"ErbB2\/HER2-specific NK cells for targeted therapy of glioblastoma","volume":"108","author":"Zhang","year":"2016","journal-title":"J. Nat. Cancer Insitute."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib145","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/mt.2014.219","article-title":"Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2\/HER2-specific chimeric antigen receptor","volume":"23","author":"Sch\u00f6nfeld","year":"2015","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.mcp.2022.101817_bib146","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s00262-012-1212-x","article-title":"Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor","volume":"61","author":"Sahm","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib147","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/CJI.0000000000000110","article-title":"Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential","volume":"39","author":"Van Ostaijen-Ten Dam","year":"2016","journal-title":"J. Immunother."},{"issue":"6","key":"10.1016\/j.mcp.2022.101817_bib148","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jcyt.2016.02.008","article-title":"Cryopreservation has no effect on function of natural killer cells differentiated in vitro from umbilical cord blood CD34+ cells","volume":"18","author":"Domogala","year":"2016","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.mcp.2022.101817_bib149","first-page":"784","article-title":"Acute GVHD in patients receiving IL-15\/4-1BBL activated NK cells following T-cell\u2013depleted stem cell transplantation, Blood","volume":"125","author":"Shah","year":"2015","journal-title":"J. Am. Soc. Hematol."},{"issue":"3","key":"10.1016\/j.mcp.2022.101817_bib150","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcyt.2014.09.007","article-title":"Challenges of cancer therapy with natural killer cells","volume":"17","author":"Klingemann","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.mcp.2022.101817_bib151","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fimmu.2015.00266","article-title":"Genetic manipulation of NK cells for cancer immunotherapy: techniques and clinical implications","volume":"6","author":"Carlsten","year":"2015","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.mcp.2022.101817_bib152","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.mcp.2022.101817_bib153","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib154","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ymthe.2016.10.011","article-title":"Masked chimeric antigen receptor for tumor-specific activation","volume":"25","author":"Han","year":"2017","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep39833","article-title":"An oxygen sensitive self-decision making engineered CAR T-cell","volume":"7","author":"Juillerat","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib156","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","article-title":"Engineering customized cell sensing and response behaviors using synthetic notch receptors","volume":"164","author":"Morsut","year":"2016","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib157","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","article-title":"Precision tumor recognition by T cells with combinatorial antigen-sensing circuits","volume":"164","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.mcp.2022.101817_bib158","series-title":"Efficient Genome Editing of Human Natural Killer Cells by CRISPR RNP","first-page":"406934","author":"Rautela","year":"2018"},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib159","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-11-262","article-title":"Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer","volume":"11","author":"Peng","year":"2013","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/j.mcp.2022.101817_bib160","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1172\/JCI45816","article-title":"Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity","volume":"121","author":"Mamessier","year":"2011","journal-title":"J. Clinic. Invest."},{"issue":"45","key":"10.1016\/j.mcp.2022.101817_bib161","doi-asserted-by":"crossref","first-page":"72961","DOI":"10.18632\/oncotarget.12150","article-title":"PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma","volume":"7","author":"Beldi-Ferchiou","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib162","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2326-6066.CIR-13-0133","article-title":"PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection","volume":"2","author":"MacFarlane","year":"2014","journal-title":"Cancer. Immunol. Res."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib163","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/imm.13094","article-title":"Genetic reprogramming for NK cell cancer immunotherapy with CRISPR\/Cas9","volume":"158","author":"Afolabi","year":"2019","journal-title":"Immunology"},{"key":"10.1016\/j.mcp.2022.101817_bib164","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.mcp.2022.101817_bib165","first-page":"365","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions, Cancer Immunology","volume":"68","author":"Hu","year":"2019","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.mcp.2022.101817_bib167","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1172\/JCI89455","article-title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"J. Clinic. Invest."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib168","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib169","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20171068","article-title":"4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses","volume":"215","author":"Menk","year":"2018","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.mcp.2022.101817_bib170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1\u03b1-secreting glioblastoma","volume":"38","author":"M\u00fcller","year":"1997","journal-title":"J. Immunother"},{"issue":"7","key":"10.1016\/j.mcp.2022.101817_bib171","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1084\/jem.192.7.1059","article-title":"DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells","volume":"192","author":"Wu","year":"2000","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.mcp.2022.101817_bib172","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.19.1.197","article-title":"Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis","volume":"19","author":"Moretta","year":"2001","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib173","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s11684-011-0159-1","article-title":"Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity","volume":"5","author":"Wu","year":"2011","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.mcp.2022.101817_bib174","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nm.2088","article-title":"Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease","volume":"16","author":"Stein","year":"2010","journal-title":"Nat. Med."},{"issue":"227","key":"10.1016\/j.mcp.2022.101817_bib175","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome\u2014long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.mcp.2022.101817_bib176","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Hacein-Bey-Abina","year":"2008","journal-title":"J. Clinic. Invest."},{"issue":"4","key":"10.1016\/j.mcp.2022.101817_bib177","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.mcp.2022.101817_bib178","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.mcp.2022.101817_bib179","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159477","article-title":"Redirecting specificity of T cells using the sleeping beauty system to express chimeric antigen receptors by mix-and-matching of VL and VH domains targeting CD123+ tumors","volume":"11","author":"Thokala","year":"2016","journal-title":"PLoS One"}],"container-title":["Molecular and Cellular Probes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850822000287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890850822000287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:17:26Z","timestamp":1760192246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890850822000287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":179,"alternative-id":["S0890850822000287"],"URL":"https:\/\/doi.org\/10.1016\/j.mcp.2022.101817","relation":{},"ISSN":["0890-8508"],"issn-type":[{"type":"print","value":"0890-8508"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The tricks for fighting against cancer using CAR NK cells: A review","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Probes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcp.2022.101817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101817"}}